Icosapent ethyl reduces ischemic events in patients with hypertriglyceridemia
KEY POINT
Patients with hypertriglyceridemia on statin therapy who received icosapent ethyl (Vascepa—Amarin) had a significant reduction in adverse cardiovascular (CV) events compared with patients receiving placebo, according to results of the REDUCE-IT trial published in the New England Journal of Medicine.
SOURCES
Bhatt DL et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
Kastelein JJP, et al. Fishing for the miracle of eicosapentaenoic acid. N Engl J Med. 2019;380(1):89–90.
Yokoyama M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8.
